Angiodynamics (ANGO) Return on Capital Employed (2011 - 2026)
Angiodynamics' (ANGO) quarterly Return on Capital Employed came in at 21.1% in Q2 2026, down 176.0% YoY from 27.77% in Q2 2025, and down 18.29% on a QoQ basis from 17.84% in Q1 2026.
Angiodynamics (ANGO) Return on Capital Employed (2011 - 2026) Analysis & Trends
Angiodynamics (ANGO) has 16 years of Return on Capital Employed data on file, last reported at 21.1% in Q2 2026.
- Quarterly Return on Capital Employed fell 176.0% year-over-year to 21.1% in Q2 2026, while the trailing twelve-month figure through May 2026 was 21.1% (down 176.0% YoY) and the FY2026 annual result came in at 20.07%, down 213.0% from the prior year.
- Return on Capital Employed declined to 21.1% in Q2 2026, from 17.84% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.63% in Q3 2023 to a low of 116.94% in Q4 2024.
- A 5-year average of 29.6% and a median of 17.23% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 11507 bps — and 2025, when it soared 10031 bps.
- Tracing ANGO's Return on Capital Employed over 5 years: stood at 6.84% in 2022, then jumped by 73 bps to 1.88% in 2023, then tumbled by 6134 bps to 116.94% in 2024, then jumped by 86 bps to 16.63% in 2025, then retreated by 27 bps to 21.1% in 2026.
- The last three Return on Capital Employed figures came in at 21.1% (Q2 2026), 17.84% (Q1 2026), and 16.63% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 18.58% |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 6.00% |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 28.11% |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 25.22% |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 5.57% |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 19.71% |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 19.76% |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 4.68% |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 3.28% |
| 10 | Angiodynamics | 655.49 Mn | 601.62 Mn | 46.77 Mn | -21.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -21.10% |
| Feb 28, 2026 | -17.84% |
| Nov 30, 2025 | -16.63% |
| Aug 31, 2025 | -18.33% |
| May 31, 2025 | -19.34% |
| Feb 28, 2025 | -23.09% |
| Nov 30, 2024 | -116.94% |
| Aug 31, 2024 | -105.08% |
| May 31, 2024 | -83.63% |
| Feb 29, 2024 | -60.92% |
| Nov 30, 2023 | -1.88% |
| Aug 31, 2023 | -0.63% |
| May 31, 2023 | -11.28% |
| Feb 28, 2023 | -7.64% |
| Nov 30, 2022 | -6.84% |
| Aug 31, 2022 | -6.89% |
| May 31, 2022 | -6.01% |
| Feb 28, 2022 | -8.74% |
| Nov 30, 2021 | -8.41% |
| Aug 31, 2021 | -7.55% |